adults with stimulant dependence, their non-dependent biological siblings and 50 unrelated healthy volunteers who had neither a personal nor a family history of dependence (Ersche et al, 2012a (Ersche et al, , 2012b . We identified significant impairments in inhibitory control abilities and abnormally high levels of impulsive and compulsive personality traits in the sibling pairs compared with the unrelated healthy volunteers. The sibling pairs also shared abnormalities in brain regions that have previously been associated with stimulant dependence, such as the inferior frontal gyrus, the amygdale, and the putamen (Chang et al, 2005; Lim et al, 2002) . Moreover, their poor performance of behavioral control on the stop-signal task was directly associated with reduced fractional anisotropy in frontal white matter brain fibers, shown in Figure 1 .
These findings shed new light on addiction vulnerability and may explain why the risk of becoming addicted to drugs is increased in people with a family history. The observation that abnormalities in brain and behavior may render individuals vulnerable to developing dependence (if resilience factors are absent), opens up new avenues for preventative and therapeutic strategies. For example, preventative approaches may consider strengthening self-control abilities in individuals at risk, while therapeutic interventions could be guided by the successful compensatory strategies used by unaffected siblings to overcome their brain abnormalities in every-day life. The identification of addiction endophenotypes in brain and behavior provide further compelling evidence that drug dependence is a disorder of the brain, with underlying abnormalities that can increase a person's risk for addiction.
Epigenetic Regulation of Synapsin Genes in Mood Disorders
The synapsins are a family of neuronal phosphoproteins consisting of SYN1 at chrXp11.3, SYN2 at chr3p25, and SYN3 at chr22q12.3 with alternative splicing leading to as many as 10 isoforms. They are involved in synaptic transmission and plasticity, as well as various stages of neurodevelop- ment, including axon outgrowth and synapse formation (Cesca et al, 2010) . All synapsins are highly concentrated at presynaptic nerve terminals of central neurons and associated with the cytoplasmic surface of synaptic vesicles, but SYN3 has markedly distinct developmental expression and subcellular distribution, suggesting divergent function (Pieribone et al, 2002) . Therefore, not surprisingly, a role for synapsins in neuropsychiatry has been suggested and, indeed, several studies have indicated that genetic variants at these genes can be associated with epilepsy, autism, schizophrenia, and bipolar disorder (BD) (Cesca et al, 2010) . Furthermore, mRNA-and protein-level postmortem brain studies have suggested dysregulation of these genes in both BD and major depressive disorder (MDD) (Cesca et al, 2010; . Thus, the study of mechanisms responsible for this dysregulation in mood disorders becomes pertinent.
In the last few years, evidence has emerged suggesting that epigenetics play a role in neuropsychiatric disorders (Jiang et al, 2008) , thus it is plausible that the dysregulation observed in synapsin expression could be attributed in part to epigenetic mechanisms. We found evidence that enrichment of H3K4me3-an epigenetic mark associated with increased transcription-at the promoters of SYN1 and SYN2, but not SYN3 is correlated with increased expression of these genes in the prefrontal cortex of patients with BD and MDD compared with controls (Cruceanu et al, 2012, see Figure 1 ). These findings are encouraging, but future research should better characterize these mechanisms by exploring the role of other chromatin epigenetic marks and brain-region specificity. In addition, the role of DNA methylation, an equally important epigenetic mechanism, should be investigated. In silico analyses have detected rich CpG islands at the proximal promoters of SYN1 (845 bp) and SYN2 (975 bp), as ............................................................................................................................................................ well as at a distal promoter of SYN3 (613 bp) (Miklem and Hillier, 2012 , see Figure 1 ). To date there is no evidence in the literature of altered DNA methylation at synapsins in mood disorders, although one study of a single schizophrenia patient suggests potentially variably methylated sites in the distal CpG island of SYN3 (Murphy et al, 2008) . Interestingly, the CpG islands at SYN1 and SYN2 are immediately preceded by regions of enriched H3K4me3 in mood disorders (Cruceanu et al, 2012, see Figure 1 ). The same is not true for SYN3, and considering this gene's distinct expression profile and potential implication throughout neurogenesis (Pieribone et al, 2002) , perhaps different mechanisms regulate SYN3. The figure illustrates our current knowledge of the synapsin genes' structure, as well as the epigenetic mechanisms that have been identified in psychiatric disorders to date.
In conclusion, brain expression differences seen in synapsin genes in mood disorders may be explained in part by differences in H3K4me3. These results need additional and independent confirmation. Moreover, considering that promoter DNA methylation can modulate gene expression and lead to neuropsychiatric phenotypes, a study of DNA methylation patterns at the synapsin promoters is warranted. On the basis of growing evidence suggesting that epigenetic mechanisms may be involved in altered regulation of synapsins in mood disorders, it would be of interest to study these genes as potential therapeutic targets or biomarkers of treatment response. Evidence is starting to emerge pointing to epigenetic marks as potential biomarkers of treatment response. For instance, for brain-derived neurotrophic factor (BDNF), (Lopez et al, 2010) showed that promoter H3K27me3 levels could serve as a biomarker of response to citalopram in MDD, and (D'Addario et al, 2012) found distinct DNA methylation patterns at the BDNF promoter in BD patients depending on mood-stabilizer and antidepressant therapy. Although no such evidence has yet emerged for synapsins, a recent study showed that lithium, one of the most commonly prescribed drugs for BD, can modulate SYN2 expression in neuronal cell types . Thus, an investigation of synapsin epigenetics in the brain compared with the periphery would be an interesting next step in elucidating their potential to serve as biomarkers for mood disorders or their treatment.
Neuroinflammation and Autism: Toward Mechanisms and Treatments
Autism spectrum disorders (ASDs) were originally described by Kanner (1943) . The relatively consistent clinical phenotype will likely be shown to comprise numerous etiologic subtypes. Approximately 10% of ASD cases are linked to disorders of genetic etiology, such as Fragile X syndrome, tuberous sclerosis, and Rett disorder. The majority of cases, however, remain idiopathic.
A role for immunological involvement in ASDs has long been hypothesized. Kanner did not comment on this in his initial descriptions, but a detailed review of the original 11 cases reveals important observations. One patient was 'kept in bed often because of colds, bronchitis, chickenpox, streptococcus infection, impetigo and rheumatic fever'. Another was 'given anterior pituitary and thyroid preparations and her father, aged 36 years, was one of those chronically thin persons, nervous energy readily expended', suggesting hyperthyroidism.
In our clinical work and review of the literature, we have been impressed by the possible role of autoimmune disorders as influencing the pathophysiology of a distinct, objectively defined etiologic subtype of ASDs. Money et al (1971) published what is widely accepted as the first connection between autism and autoimmune disorders. They described a family in which the youngest child had multiple
